Windy City Media Group Frontpage News

THE VOICE OF CHICAGO'S GAY, LESBIAN, BI, TRANS AND QUEER COMMUNITY SINCE 1985

home search facebook twitter join
Gay News Sponsor Windy City Times 2021-12-08
DOWNLOAD ISSUE
Donate

Sponsor


  WINDY CITY TIMES

Norvir Patent Under Fire at NIH Meeting
by Bob Roehr
2004-06-02

This article shared 5070 times since Wed Jun 2, 2004
facebook twitter google +1 reddit email


Should Abbott Laboratories' exorbitant price increase for the HIV drug Norvir (ritonavir) trigger a never before used law and allow other companies to produce the drug. The National Institutes of Health held a public meeting May 25 to consider the question.

Ritonavir was developed as a protease inhibitor (PI) and has the unique property of slowing down liver metabolism or clearance of all PIs so that they stay in the bloodstream longer. But because of side effects and limited efficacy ritonavir seldom is used as a PI but almost exclusively in small, sub-therapeutic doses, to 'boost' other PIs.

Abbott increased the price of the drug by 400% last December, from $1.71 to $8.57 a day. That generated a storm of protest from all corners of the HIV community because it affected every other combination therapy that uses PIs, which is more than half of the patients on therapy.

NIH contributed about $3.5 million to the very early development of ritonavir and holds four of the six patents on the drug. This brought it under the purview of the Bayh-Dole Act, a law passed in 1980 to encourage commercialization of basic research funded by the federal government.

The nonprofit group Essential Inventions charged that Abbott's price increase violated the public benefits portion of Bayh-Dole and the company should no longer have exclusive use of the patents to manufacture ritonavir. In January it petitioned NIH to consider using the law to let others do so.

Mark L. Rohrbaugh, director of the NIH Office of Technology Transfer, said the meeting was to gather information from constituents 'that might warrant the exercise of march-in rights' under Bayh-Dole. He will make a recommendation to NIH Director Elias Zerhouni, who will decide whether or not such regulatory action should be initiated.

Any decision from that process would be subject to legal review and appeal through the federal courts. The march-in provision of the law has never been used before so there is no precedent to guide the participants.

CHARGES

John Erickson headed up research into protease inhibitors at Abbott from 1985 to 1991, before moving to the National Cancer Institute, and later starting a small pharmaceutical company.

He said the NIH grant that began in 1988 and ran for five years 'gave a much needed boost' to Abbott's PI program. 'Without the prestige and dollars it is unlikely' that the research would have received 'the internal [company] funding support needed to make the program thrive.'

'There was nothing unusual about Abbott's lack of enthusiasm for HIV drug discovery research at that time,' interest in HIV research among big pharma was the exception rather than the rule. Erickson said, 'The [NIH] grant gave us the opportunity to take a risk that management was not yet prepared to take on its own.'

Bob Huff, the editor of Treatment News at the Gay Men's Health Crisis (GMHC), offered a pointed and devastating critique of Abbott's 'abuse of their patent.' Increasing the price of Norvir, but not of its own PI Kaletra that is co-formulated with the drug made it clear that 'the practical and intended effect was to position Kaletra in advantage to its competitors.'

Perhaps most crucial is the effect the price increase will have on the development of future PIs that use the boosting approach, Huff said. It will greatly increase the cost of conducting post-approval phase IV clinical trials that are most useful in determining the best use of all drugs.

It leaves other companies at the mercy of Abbott in terms of the total market cost of their drug. Huff said, 'It's difficult enough to project market conditions for new HIV drugs that don't need Norvir; it's very unlikely that a corporate market analysis will ever again justify investment in drugs of this type.'

This is contrary to the very purpose of Bayh-Dole, which is to foster innovation and move products into the marketplace.

James Love, president of Essential Inventions that filed the march-in provision, questioned the justification for such an astronomical price increase 'eight years after the product hit the market.' Ritonavir had generated a billion dollars in sales in the first five years on the market and remained profitable at the time of the increase. 'It's become a blockbuster product.'

The price increase last December 'only applied in America.' Love asked, 'Is it appropriate to take a government-funded invention and price it five to ten times higher in the United States than you charge in other high income countries?'

He said it was 'an attempt to monopolize the protease inhibitor market' in this country. Eight Senators, led by John McCain, R-Ariz., and Fritz Hollings, D-SC, have asked the Federal Trade Commission to investigate.

Love called the march-in clause 'the safeguard of Bayh-Dole.' If Abbott can do those things, 'Is there anything that you can't do to trigger the march-in provision?'

The march-in provision has not been used in the 24 years that Bayh-Dole has been in effect. Love said, this extraordinary case demands action. He warned that failure to do so would lead to additional legislation.

'Abbott Laboratories holds a virtual monopoly stake in the life expectancy of the majority of Americans living with HIV,' said Benjamin Young, a Denver physician. He represented the Organization of HIV Healthcare Providers, a group of HIV treatment specialists that sprang up in response to the price increase.

He called the increase 'unprecedented in the history of the pharmaceutical industry,' and noted the public outcry years ago that greeted a 40% increase in the price of AZT by Burroughs-Wellcome and ultimately lead to it being rolled back.

DEFENSE

Several speakers familiar with the legislative history of Bayh-Dole said it was never intended to regulate price. But that was within the context of a stand-alone drug. None of the speakers addressed the issues raised when a drug is used in combination with others, which is a matrix of issues that was not envisioned during that earlier debate when the legislation was passed.

Jeffrey Leiden, Abbott's president for the pharmaceutical products group, defended the company. He said Norvir was entirely the product of Abbott's research and they spent more than $300 million to bring it to market. That sum is less than half of what the pharmaceutical industry claims it takes to bring a typical new drug to market.

He outlined the 'extraordinary steps' the company has taken to ensure access to the drug for those who cannot afford it. He did not acknowledge that many of those problems were created by the company's price increase.

Leiden said that when they reviewed the effectiveness of PIs using a ritonavir boost, 'What was particularly striking to us was the disparity of value of the various components.' That was Abbott's justification for the price increase; it did not reflect their cost of developing the drug or necessarily their commitment of an investment in further HIV research.

Speaking with reporters after the meeting, Rohrbaugh said he had no timeline for deciding whether to proceed to a formal march-in procedure or not.


This article shared 5070 times since Wed Jun 2, 2004
facebook twitter google +1 reddit email

  ARTICLES YOU MIGHT LIKE

Gay News

Lambda Legal issues assessment of Biden-Harris administration's work for LGBTQ+, HIV communities
2022-01-22
-- From a press release - Washington, D.C. — Lambda Legal released a new comprehensive report that assesses the Biden-Harris administration's first year with respect to its impact on the LGBTQ+ community and everyone living with HIV. While the report identifies significan ...


Gay News

Gilead: Patients received fake HIV drugs
2022-01-20
Gilead Sciences Inc said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years, endangering patients, Reuters reported. The drugmaker ...


Gay News

AIDS Foundation Chicago cancels World of Chocolate due to COVID-19 surge
2022-01-19
-- From a press release - CHICAGO — AIDS Foundation Chicago (AFC) has made the difficult decision to cancel its World of Chocolate event, the organization's largest winter fundraiser, due to the recent Omicron surge across ...


Gay News

NATIONAL California report, AIDS foundation CEO, QueerArt, intersex bill
2022-01-09
California law enforcement officials conduct body searches on Black and transgender people more often than on white and cisgender people, according to a new report from California's Racial and Identity Profiling Advisory (RIPA) Board, LGBTQ Na ...


Gay News

FDA approves injectable PrEP
2021-12-24
The U.S. Food and Drug Administration (FDA) approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 77 pounds for pre-exposure prophylaxis (PrEP) to ...


Gay News

Legislation to address disparities facing LGBTQ+ seniors, people with HIV/AIDS
2021-12-22
On Dec. 16, Pride Action Tank, OUTreach and Equality Illinois hosted a virtual "breakfast" to discuss issues facing LGBTQ+ seniors and persons with HIV/AIDS as well as legislative policies created to address them. "Advocating for Change" ...


Gay News

CDC study shows Black and Latinx LGBTQ+ men remain most affected by HIV/AIDS
2021-12-22
A new study from the Centers for Disease Control and Prevention (CDC) showed Black and Latinx gay and bisexual men continue to be more affected by HIV/AIDS than white members of the LGBTQ+ community. Howard Brown ...


Gay News

World of Chocolate fundraiser returns Feb. 11, benefits AIDS Foundation Chicago
2021-12-20
--From a press release - After a two-year hiatus, AIDS Foundation Chicago (AFC) is proud to announce the return of its famed World of Chocolate fundraiser taking place on Friday, Feb/ 11 at Union Station, 500 W. Jackson Blvd. Inspired by ...


Gay News

HIV AT 40: Longtime advocate Gregg Gonsalves talks activist roots, Larry Kramer and COVID
2021-12-08
When it comes to dealing with HIV/AIDS, few people have been on the front lines—in the areas of activism, research and instruction—like Gregg Gonsalves. Gonsalves, a MacArthur fellow, is an expert in policy modeling on infectious ...


Gay News

AIDS Garden Chicago supporters, CDPH official commemorate World AIDS Day with event
2021-12-01
AIDS Garden Chicago supporters and the Chicago Department of Public Health (CDPH) commemorated the 34th annual World AIDS Day on Dec. 1 at the Belmont Yacht Club with a sneak preview of the garden. The 2.5-acre ...


Gay News

Director Paris Barclay talks about virtual reading of 'The Normal Heart'
2021-12-01
The seminal Larry Kramer play The Normal Heart—which focuses on the rise of the HIV/AIDS epidemic in New York City in the early 1980s, through the perspective of the character Ned Weeks—is the subject of a ...


Gay News

State Rep. Greg Harris not seeking re-election
2021-11-29
Illinois state Rep. Greg Harris—the first openly gay and HIV-positive state leader in the General Assembly—announced that he won't seek re-election and will leave the House when his term expires in early 2023, The Chicago Tribune ...


Gay News

Five Worth Finding: World AIDS Day, 'Benedetta,' books, wine in a can
2021-11-26
—World AIDS Day event at Belmont Harbor: —The Chicago Parks Foundation will hold a World AIDS Day event on Dec. 1, 9-10:30 a.m., at the Belmont Harbor Yacht Club. Antonio King, LGBTQ health and outreach liaison ...


Gay News

Virtual reading, Q&A of 'The Normal Heart' with mostly LGBTQ+ and/or BIPOC cast on Dec. 4
2021-11-26
ONE Archives Foundation, in collaboration with Invisible Histories Project, announced today that a brand-new Q&A will follow an encore and final presentation of the historic virtual reading of Larry Kramer's Tony-winning play The Normal Heart. The ...


Gay News

World AIDS Day events on tap
2021-11-26
World AIDS Day takes place every year on Dec. 1. During this year—which marks the 40th anniversary since HIV was officially discovered—here are some of the events taking place (locally, regionally and nationally) on, before and ...


 



Copyright © 2022 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
our online archives. Single copies of back issues in print form are
available for $4 per issue, older than one month for $6 if available,
by check to the mailing address listed below.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.
All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transegender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.

 
 

TRENDINGBREAKINGPHOTOS






Donate


About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots      OUT! Guide     
Identity      BLACKlines      En La Vida      Archives      Advanced Search     
Windy City Queercast      Queercast Archives     
Press  Releases      Join WCMG  Email List      Email Blast      Blogs     
Upcoming Events      Todays Events      Ongoing Events      Bar Guide      Community Groups      In Memoriam      Outguide Categories      Outguide Advertisers      Search Outguide      Travel      Dining Out      Privacy Policy     

Windy City Media Group publishes Windy City Times,
The Bi-Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.